AGN News and Press, Allergan plc From 09/25/19

Evolus, Inc. ( EOLS ) obtained impressive results from its Phase III trial. Also, it received its first revenue in h1 2019, which investors will most likely appreciate. With that, the market appears to be too optimistic. The company is valued having an enterprise value of $531 million and an E...

Merger activity remained unchanged last week with two new deals announced and seven deals closing. Deal Statistics: New Deals: The acquisition of Alder BioPharmaceuticals (ALDR) by H. Lundbeck A/S for $1.95 billion. Under the terms of the agreement, Alder stockholders will be of...

AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and growth stocks for the better part of the last decade. These two pharma giants have generated total returns on capital (including dividends) of 52% and 97%, respectively, over the last five years.  None...

Editor's note: Seeking Alpha is proud to welcome Altimetry as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Many M&A deals suff...

Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Libsyn By Nathaniel E. Baker The Fortune Teller joins the Marketplace Roundtable Podcast to discuss his investing experience as r...

With one product candidate at Phase 3 of development and expecting completion in early 2020, Aclaris Therapeutics ( ACRS ) is a name to be followed carefully. The Phase 3 trial is estimated to be completed on January 15, 2020. With that said, the company’s cash burn rate is very signifi...

DUBLIN , Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of ...

Merger activity increased last week with two new deals announced and two deals closing. Deal Statistics: New Deals: The acquisition of United Community Financial (UCFC) by First Defiance Financial (FDEF) for $473 million in an all-stock deal. Under the terms of the merger agre...

DUBLIN , Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) today ...

Amgen ( AMGN ) and its partner Allergan ( AGN ) were able to achieve positive results in a comparative clinical study between their candidates ABP-798 and Rituxan. These positive results set up the biosimilar to potentially compete against Rituxan. This newly reported study focused on pa...